Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial).
|Title||Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial).|
|Publication Type||Journal Article|
|Year of Publication||2015|
|Authors||Mewton, N., T. T. Cung, O. Morel, G. Cayla, E. Bonnefoy-Cudraz, G. Rioufol, D. Angoulvant, P. Guerin, M. Elbaz, N. Delarche, P. Coste, G. Vanzetto, M. Metge, J. - F. Aupetit, B. Jouve, P. Motreff, C. Tron, J. - N. Labeque, P. G. Steg, Y. Cottin, G. Range, J. Clerc, P. Coussement, F. Prunier, F. Moulin, O. Roth, L. Belle, P. Dubois, P. Barragan, M. Gilard, C. Piot, P. Colin, M. - C. Morice, J. - P. Monassier, O. Ider, J. L. P. Dubois-Randé, T. Unterseeh, H. Lebreton, T. Beard, D. Blanchard, G. Grollier, V. Malquarti, P. Staat, A. Sudre, M. J. Hansson, E. Elmer, I. Boussaha, C. Jossan, A. Torner, M. Claeys, D. Garcia-Dorado, and M. Ovize|
|Corporate Authors||CIRCUS Study Investigators|
|Journal||American heart journal|
|Date Published||2015 Jun|
|Keywords||Biological Markers, Coronary Angiography, Cyclosporine, Double-Blind Method, Echocardiography, Electrocardiography, Female, Humans, Male, Myocardial Infarction, Percutaneous Coronary Intervention, Prospective Studies, Time Factors, Treatment Outcome|
BACKGROUND: Both acute myocardial ischemia and reperfusion contribute to cardiomyocyte death in ST-elevation myocardial infarction (STEMI). The final infarct size is the principal determinant of subsequent clinical outcome in STEMI patients. In a proof-of-concept phase II trial, the administration of cyclosporine prior to primary percutaneous coronary intervention (PPCI) has been associated with a reduction of infarct size in STEMI patients.
METHODS: CIRCUS is an international, prospective, multicenter, randomized, double-blinded, placebo-controlled trial. The study is designed to compare the efficacy and safety of cyclosporine versus placebo, in addition to revascularization by PPCI, in patients presenting with acute anterior myocardial infarction within 12 hours of symptoms onset and initial TIMI flow ≤1 in the culprit left anterior descending coronary artery. Patients are randomized in a 1:1 fashion to 2.5 mg/kg intravenous infusion of cyclosporine or matching placebo performed in the minutes preceding PCI. The primary efficacy end point of CIRCUS is a composite of 1-year all-cause mortality, rehospitalization for heart failure or heart failure worsening during initial hospitalization, and left ventricular adverse remodeling as determined by sequential transthoracic echochardiography. Secondary outcomes will be tested using a hierarchical sequence of left ventricular (LV) ejection fraction and absolute measurements of LV volumes. The composite of death and rehospitalization for heart failure or heart failure worsening during initial hospitalization will be further assessed at three years after the initial infarction.
RESULTS: Recruitment lasted from April 2011 to February 2014. The CIRCUS trial has recruited 975 patients with acute anterior myocardial infarction. The 12-months results are expected to be available in 2015.
CONCLUSIONS: The CIRCUS trial is testing the hypothesis that cyclosporine in addition to early revascularization with PPCI compared to placebo in patients with acute anterior myocardial infarction reduces the incidence of death, heart failure and adverse LV remodeling at one-year follow-up.
|Alternate Journal||Am. Heart J.|